Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis finds that the number of new medicines launched in ...

Introduction Over the past few years, the European Union has been actively working to overhaul its pharmaceutical legislative framework to better address unmet medical needs, such as those ...

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euro ...

Prof. Musallam’s recognition by EHA affirms his role as a transformative figure in hematology and underscores the UAE’s growing influence in global medical research. His work continues to inspire a ...

Shares in Neuren Pharmaceuticals advanced in morning trade after Macquarie initiated coverage of the biopharmaceutical company with an 'outperform' rating.

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss ...